Maria Mancini
Chief Operating Officer bij CHAMPIONS ONCOLOGY, INC.
Profiel
Maria Mancini is currently the Chief Operating Officer at Champions Oncology, Inc. She previously worked as the Research Director at Biomodels LLC from 2011 to 2015.
Dr. Mancini holds a doctorate degree from the University of Maine.
Actieve functies van Maria Mancini
| Bedrijven | Functie | Begin |
|---|---|---|
| CHAMPIONS ONCOLOGY, INC. | Chief Operating Officer | - |
Eerdere bekende functies van Maria Mancini
| Bedrijven | Functie | Einde |
|---|---|---|
Biomodels LLC
 Biomodels LLC BiotechnologyHealth Technology Biomodels LLC offers customized solutions for the development of disease models in the fields of biology, behavior, and neuroscience. Biomodels is based in Boston, MA and was founded in 1997 with the aim of creating a more useful interface between leading academic researchers and the pharmaceutical industry. The private company provides a wide range of behavioral tests for examining treatment for neurological disorders. The company has developed several models of fibrosis to reflect common inflammatory diseases. The company also offers in vitro models for drug response assessment, metabolic disease studies, microbiome research services, and preclinical research services for cancer, radiation countermeasures, and inflammatory diseases. | Chief Tech/Sci/R&D Officer | 01-03-2015 |
Opleiding van Maria Mancini
| University of Maine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CHAMPIONS ONCOLOGY, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Biomodels LLC
Biomodels LLC BiotechnologyHealth Technology Biomodels LLC offers customized solutions for the development of disease models in the fields of biology, behavior, and neuroscience. Biomodels is based in Boston, MA and was founded in 1997 with the aim of creating a more useful interface between leading academic researchers and the pharmaceutical industry. The private company provides a wide range of behavioral tests for examining treatment for neurological disorders. The company has developed several models of fibrosis to reflect common inflammatory diseases. The company also offers in vitro models for drug response assessment, metabolic disease studies, microbiome research services, and preclinical research services for cancer, radiation countermeasures, and inflammatory diseases. | Health Technology |
